In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

U.S. stock indexes rallied at midday Wednesday as President Donald Trump said he has "no intention" of firing Federal Reserve ...

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Bristol-Myers Squibb (NYSE: BMY) is scheduled to announce Q1 earnings results on Thursday, April 24th, before market open.

Fintel reports that on April 22, 2025, Piper Sandler initiated coverage of Bristol-Myers Squibb Company - Preferred Security ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Citi lowered the firm’s price target on Bristol Myers (BMY) to $51 from $55 and keeps a Neutral rating on the shares. The stock is under ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...